miR‑181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1

摘要: Multidrug resistance (MDR) remains the major cause of disease relapse and poor prognosis in adults with acute myeloid leukemia (AML). Emerging evidence shows that drug not only exists against conventional chemotherapeutic drugs, but also limits efficacy new biological agents. Therefore, it is important to elucidate mechanisms through which AML patients develop resistance. MicroRNAs have been shown play an role regulating chemotherapy AML. A detailed understanding microRNA are clinically relevant may enhance our ability predict overcome Here, we demonstrated, for first time, miR-181b was decreased significantly human multidrug-resistant cells relapsed/refractory patient samples. Overexpression increased sensitivity cytotoxic agents promoted drug-induced apoptosis. Moreover, inhibited HMGB1 Mcl-1 expression by direct binding their 3'-untranslated regions. In addition, expressed at high levels suppression via RNA interference sensitized induced conclusion, these results provide a strong rationale development miR-181b-based therapeutic strategies enhancement treatment.